Lilly, Nvidia to establish $1B AI co-innovation lab in San Francisco
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
Pharmaceutical
-
INCOG BioPharma investing additional $200M to expand Fishers campus
INCOG, which now employs just more than 400 people in Fishers, plans to have nearly 1,000 people working at its 21-acre campus by 2030.
Read More -
Q&A with Cory Lewis, whose emphasis on collaboration has driven INCOG’s rapid growth
Lewis sat down with IBJ to talk about his leadership style and the role of cycling in his life.
Read More -
Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer
The Indianapolis-based drugmaker said the supercomputer will power an “AI factory” designed to accelerate drug discovery and development.
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More
Articles
Former GLP-1 users regain lost weight after about 18 months, study says
People who stop taking GLP-1 drugs such as Ozempic, Wegovy and Zepbound for weight loss are projected to regain their shed pounds within about 1-½ years, a review of existing research has found.
Pharmaceutical company planning to employ 300 workers in Greenfield
The plant will focus on serving health care companies by developing and commercializing medical devices, drug delivery systems and combination products.
First GLP-1 weight-loss pill now available, with pledge of abundant supply
Novo Nordisk is aiming to avoid losing ground to its main rival, Eli Lilly, which is seeking regulatory approval for its own GLP-1 weight-loss pill.
Indiana attorney general sues Lilly over insulin prices
Attorney General Todd Rokita said the lawsuit, filed last Wednesday in the Lake County Superior Court, is part of his office’s intensifying efforts to lower insulin prices and improve health care affordability.
US regulators approve Wegovy pill for weight loss, giving Novo Nordisk an edge over Lilly
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Lilly’s growth explosion tests state’s workforce development
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
IU doctor takes expert role as FDA weighs changes to testosterone therapy regulation
Dr. Helen Bernie said on a Dec. 10 panel hosted by the U.S. Food and Drug Administration that serum testosterone “is one of the most powerful yet underutilized biomarkers for men’s health.”
Lilly to build $6B plant in Alabama in 3rd of 4 big US investments
Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
UK and US agree zero-tariff deal on pharmaceuticals
The Trump administration said that in return, U.K. drugs firms committed to invest more in the U.S. and create more jobs.
Lilly cuts prices on Zepbound vials sold on LillyDirect
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
Trump administration says lower prices for 15 Medicare drugs will save taxpayers billions of dollars
The latest negotiated prices apply to some of the prescription medications on which Medicare spends the most money.
Lilly rolling out direct-to-employer obesity drug coverage
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Judge formally approves Purdue Pharma opioid settlement, with Sacklers paying up to $7B
Thousands of victims of the opioid epidemic could be paid thousands of dollars each, with a portion of the money distributed next year to some people who had OxyContin prescriptions and their survivors.
The surprising new use for GLP-1s: Alcohol and drug addiction
As GLP-1 drugs for weight loss and diabetes drugs such as Zepbound and Mounjaro generate billions in sales, researchers at Eli Lilly and Co. and other pharma companies are exploring their potential for other purposes.
UPDATE: Eli Lilly stock reaches new high, tops $1,000-per-share mark
Lilly’s shares have taken off in the wake of several significant deals and after it received fast-track regulatory review for highly anticipated weight-loss pill orforglipron.
Trump unveils deal with Lilly, Novo to expand coverage, lower costs on obesity drugs
Thursday’s announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters.
UPDATE: White House nears deal with Lilly, Novo to slash obesity drug prices for Medicare
The deal is seen as one of the most significant in the administration’s current drug-pricing push, given the potential effect on public health and spending on health care.
Eli Lilly to build $3B manufacturing site in Netherlands
The facility is expected to produce oral medications, including Lilly’s highly anticipated GLP-1 pill for weight loss, orforglipron.
IU-Lilly study to explore drugs’ impact on job productivity
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.